The Litigation Group’s jury research and selection guidance provided leading human therapeutic/biotechnology company Amgen with valuable support that helped to win a case against Roche in Boston, Mass.
Roche was accused of using Amgen’s innovations, which revolutionized the treatment of people with anemia; Amgen’s Epogen and Aranesp products are approved by the FDA to treat people with chronic kidney failure and cancer patients receiving chemotherapy. The jury found that Roche’s pegylated-erythropoietin (peg-EPO) product, Mircera, infringes upon 11 Amgen EPO patent claims.
“It’s nice to see Amgen’s position so thoroughly vindicated,” said Amgen attorney, Lloyd Day. “It has been a long time coming.”
Amgen Wins a Decisive Victory in Patent Battle Over Roche’s Anemia Drug
